NF decline but stable QOL in 1st year after temozolomide-based chemoradiotherapy

November 25, 2019

A secondary analysis of the NRG Oncology clinical trial NRG-RTOG 0424, which initially reported a 73.1% 3-year overall survival rate, shows a decline in neurocognitive function (NCF) for half of the trial participants with high risk, low-grade gliomas (HR-LGGs) up to a year after receiving concurrent chemoradiotherapy with temozolomide. However, the analysis also concluded that on average the quality of life (QOL) of patients either remained stable or improved up to a year following temozolomide-based chemoradiotherapy treatment. These results were presented during the Plenary Session at the Society for Neuro-Oncology's (SNO) annual meeting in Phoenix, Arizona.

The Phase II trial, NRG-RTOG 0424, accrued 129 evaluable patients with HR-LGGs to receive daily temozolomide plus concurrent radiotherapy for 6 weeks followed by temozolomide for 12 cycles. Ninety-three patients completed at least one NCF and QOL measurement. NCF tests were performed at the end of treatment, again at 6 months following treatment, and at one year following treatment. Patients who completed NCF and QOL measurements had better clinician rated neurologic function than patients who did not complete the measurements. At 6 months after treatment, 55-59% of trial participants completed NCF and QOL measurements and 54-57% of participants completed measurements at one year following treatment.

"The secondary analysis of NRG-RTOG 0424 show that a large subset of patients are vulnerable to neurocognitive decline after chemoradiotherapy with temozolomide followed by adjuvant temozolomide.Similarly, while general QOL subscales were stable on average, a subset of patients reported diminished brain related QOL over time. Patients in the EORTC High Risk Group and with tumors crossing the midline were at greater risk for these adverse outcomes. These data further support the importance of monitoring neurocognitive function and QOL in trials comparing this treatment regimen with other active treatment regimens such as the CODEL trial (Alliance N0577; EORTC 26081-22086; NRG 1071; NCIC CEC.6) and for further developing our understanding of risk factors for such outcomes," stated Jeffrey S. Wefel, PhD, ABPP, of The University of Texas MD Anderson Cancer Center and lead author of the NRG-RTOG 0424 secondary analysis.

NCF deterioration occurred in 50% of patients at 6 months and 40% of patients at one year post-treatment. These NCF declines were most notable in Hopkins Verbal Learning Test (HVLT) and Trail Making Tests (TMTA and TMTB). Patients who exhibited deterioration in the HVLT at one year post-treatment had a significantly greater decrease in MOS-Cognitive Function (MOS-CF). FACT Emotional and Functional Well-Being subscales improved over time. No NCF test at baseline was independently associated with overall survival.
-end-
NRG-RTOG 0424 is supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NRG Oncology NCORP) from the National Cancer Institute (NCI).

Citation

Wefel JS, Pugh SL, Choucair AK, Fisher BJ, Fox S, Meyers CA, Ashby LS, Mikkelsen T, Glass J, Yu HHM, Howard SP, Movsas B, Mehta MP. (2019, November). Neurocognitive function (NCF) and quality of life (QOL) results from a phase II study (RTOG 0424) of temozolomide-based chemoradiotherapy regimen for high risk low-grade gliomas (HR-LGG). Paper presented at the annual meeting of the Society for Neuro-Oncology, Phoenix, AZ.

About NRG Oncology

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology's extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trials Network. http://www.nrgoncology.org

NRG Oncology

Related Chemoradiotherapy Articles from Brightsurf:

The natural artistry of disease: a wintry landscape in the eye
Researchers from Tokyo Medical and Dental University (TMDU) report a case of frosted branch angiitis in a woman presenting years after being treated for leukemia-lymphoma with allogeneic human stem cell transplant.

Experimental glioblastoma therapy shows curative powers in mice models
Houston Methodist researchers used a second-generation prodrug called MP-Pt(IV) to target the deadly cells of glioblastoma tumors and found mice harboring human glioblastoma tumors in their brains had greatly enhanced survival and weight gain when given the newly developed prodrug.

Mass General researchers create bioluminescent tag to detect DNA break repair
A new bioluminescent reporter that tracks DNA double stranded break (DSB) repair in cells has been developed by researchers from Massachusetts General Hospital (MGH) and the Academia Sinica in Taiwan.

Shorter radiotherapy treatment for bowel cancer patients during COVID-19
An international panel of cancer experts has recommended a one-week course of radiotherapy and delaying surgery as the best way to treat patients with bowel cancer during the COVID-19 pandemic.

Radiation/immunotherapy combo shows promise for recurrent/metastatic head and neck cancers
A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

'Watch-and-Wait' strategy could safely replace surgery in more than 20% of rectal cancers
This therapeutic approach is still far from being mainstream practice.

Standard of care chemoradiation for Stage III NSCLC is superior to two tested alternatives
Lung cancer is the leading cause of cancer death in the United States and approximately 75-80% of all cases are non-small cell lung cancer (NSCLC).

Immunotherapy is safe following chemoradiotherapy for women with node-positive cervical cancer
Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer.

NF decline but stable QOL in 1st year after temozolomide-based chemoradiotherapy
A secondary analysis of the NRG Oncology clinical trial NRG-RTOG 0424, which initially reported a 73.1% 3-year overall survival rate, shows a decline in neurocognitive function (NCF) for half of the trial participants with high risk, low-grade gliomas (HR-LGGs) up to a year after receiving concurrent chemoradiotherapy with temozolomide.

Machine learning improves the diagnosis of patients with head and neck cancers
Researchers from Charité - Universitätsmedizin Berlin and the German Cancer Consortium (DKTK) have successfully solved a longstanding problem in the diagnosis of head and neck cancers.

Read More: Chemoradiotherapy News and Chemoradiotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.